Serum IGF-I and C-reactive protein in healthy black and white young men: The CARDIA male hormone study

Growth Hormone and IGF Research

Volumn 19, Issue 5, 2009, Pages 420-425

  Colangelo, Laura A ^a   Chiu, Brian ^a   Kopp, Peter ^a   Liu, Kiang ^a   Gapstur, Susan M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

C reactive protein; Insulin like growth factor binding protein 3; Insulin like growth factor I; Men

Indexed keywords

C REACTIVE PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CAUCASIAN; CONTROLLED STUDY; HUMAN; LINEAR REGRESSION ANALYSIS; MALE; NEGRO; NORMAL HUMAN; NUTRITION; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE; SMOKING;

ADULT; AFRICAN AMERICANS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MALE;

EID: 70349345810     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2008.12.002     Document Type: Article

References (64)

1. Collett-Solberg P.F., and Cohen P. The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol. Metab. Clin. North Am. 25 (1996) 591-614
2. Cohen P. Overview of the IGF-I system. Horm. Res. 65 Suppl. 1 (2006) 3-8
3. De Benedetti F., Meazza C., Oliveri M., et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 142 (2001) 4818-4826
4. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. New Engl. J. Med. 340 (1999) 448-454
5. De Benedetti F., Alonzi T., Moretta A., et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J. Clin. Invest. 99 (1997) 643-650
6. Thissen J.P., and Verniers J. Inhibition by interleukin-1 beta and tumor necrosis factor-alpha of the insulin-like growth factor-I messenger ribonucleic acid response to growth hormone in rat hepatocyte primary culture. Endocrinology 138 (1997) 1078-1084
7. Willerson J.T., and Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 109 (2004) II2-II10
8. Kaushal K., Heald A.H., Siddals K.W., et al. The impact of abnormalities in IGF and inflammatory systems on the metabolic syndrome. Diabetes Care 27 (2004) 2682-2688
9. Heald A.H., Anderson S.G., Ivison F., Laing I., Gibson J.M., and Cruickshank K. C-reactive protein and the insulin-like growth factor (IGF)-system in relation to risk of cardiovascular disease in different ethnic groups. Atherosclerosis 170 (2003) 79-86
10. Kuller L.H., Tracy R.P., Shaten J., and Meilahn E.N. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple risk factor intervention trial. Am. J. Epidemiol. 144 (1996) 537-547
11. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New Engl. J. Med. 336 (1997) 973-979
12. Sesti G., Sciacqua A., Cardellini M., et al. Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care 28 (2005) 120-125
13. Alexandraki K., Piperi C., Kalofoutis C., Singh J., Alaveras A., and Kalofoutis A. Inflammatory process in type 2 diabetes: the role of cytokines. Ann. N.Y. Acad. Sci. 1084 (2006) 89-117
14. Il'yasova D., Colbert L.H., Harris T.B., et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol. Biomar. Prev. 14 (2005) 2413-2418
15. Trichopoulos D., Psaltopoulou T., Orfanos P., Trichopoulou A., and Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol. Biomar. Prev. 15 (2006) 381-384
16. Chan J.M., Stampfer M.J., Giovannucci E., et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 (1998) 563-566
17. Hankinson S.E., Willett W.C., Colditz G.A., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351 (1998) 1393-1396
18. Ma J., Pollak M.N., Giovannucci E., et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl. Cancer Inst. 91 (1999) 620-625
19. Yu H., Spitz M.R., Mistry J., Gu J., Hong W.K., and Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J. Natl. Cancer Inst. 91 (1999) 151-156
20. Street M.E., de'Angelis G., Camacho-Hubner C., et al. Relationships between serum IGF-I, IGFBP-2, interleukin-1beta and interleukin-6 in inflammatory bowel disease. Horm. Res. 61 (2004) 159-164
21. Latif Z., McMillan D.C., Wallace A.M., et al. The relationship of circulating insulin-like growth factor 1, its binding protein-3, Prostate-specific antigen and C-reactive protein with disease stage in prostate cancer. BJU Int. 89 (2002) 396-399
22. Eivindson M., Nielsen J.N., Gronbaek H., Flyvbjerg A., and Hey H. The insulin-like growth factor system and markers of inflammation in adult patients with inflammatory bowel disease. Horm. Res. 64 (2005) 9-15
23. Underwood L.E., Thissen J.P., Lemozy S., Ketelslegers J.M., and Clemmons D.R. Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm. Res. 42 (1994) 145-151
24. Smith W.J., Underwood L.E., and Clemmons D.R. Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children and adults. J. Clin. Endocrinol. Metab. 80 (1995) 443-449
25. Rajpathak S.N., McGinn A.P., Strickler H.D., et al. Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Horm. IGF Res. 18 (2008) 166-173
26. Fontana L., Klein S., and Holloszy J.O. Long-term low-protein, low-calorie diet and endurance exercise modulate metabolic factors associated with cancer risk. Am. J. Clin. Nutr. 84 (2006) 1456-1462
27. Ajani U.A., Ford E.S., and Mokdad A.H. Dietary fiber and C-reactive protein: findings from national health and nutrition examination survey data. J. Nutr. 134 (2004) 1181-1185
28. Niu K., Hozawa A., Kuriyama S., et al. Dietary long-chain n-3 fatty acids of marine origin and serum C-reactive protein concentrations are associated in a population with a diet rich in marine products. Am. J. Clin. Nutr. 84 (2006) 223-229
29. Delaney N.L., Esquenazi V., Lucas D.P., Zachary A.A., and Leffell M.S. TNF-alpha, TGF-beta, IL-10, IL-6, And INF-gamma alleles among African Americans and Cuban Americans. Report of the ASHI minority workshops: part IV. Hum. Immunol. 65 (2004) 1413-1419
30. Berrigan D., Potischman N., Dodd K.W., et al. Race/ethnic variation in serum levels of IGF-I and IGFBP-3 in US adults. Growth Horm. IGF Res. (2008)
31. Perez-Stable E.J., Herrera B., Jacob III P., and Benowitz N.L. Nicotine metabolism and intake in black and white smokers. JAMA 280 (1998) 152-156
32. Hart P., Farrell G.C., Cooksley W.G., and Powell L.W. Enhanced drug metabolism in cigarette smokers. Br. Med. J. 2 (1976) 147-149
33. Gapstur S.M., Gann P.H., Kopp P., Colangelo L., Longcope C., and Liu K. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiol. Biomar. Prev. 11 (2002) 1041-1047
34. Raitakari M., Mansikkaniemi K., Marniemi J., Viikari J.S., and Raitakari O.T. Distribution and determinants of serum high-sensitive C-reactive protein in a population of young adults: the Cardiovascular Risk in Young Finns Study. J. Int. Med. 258 (2005) 428-434
35. Ohsawa M., Okayama A., Nakamura M., et al. CRP levels are elevated in smokers but unrelated to the number of cigarettes and are decreased by long-term smoking cessation in male smokers. Prev. Med. 41 (2005) 651-656
36. Pai J.K., Hankinson S.E., Thadhani R., Rifai N., Pischon T., and Rimm E.B. Moderate alcohol consumption and lower levels of inflammatory markers in US men and women. Atherosclerosis 186 (2006) 113-120
37. King D.E., Mainous III A.G., Geesey M.E., and Woolson R.F. Dietary magnesium and C-reactive protein levels. J. Am. Coll. Nutr. 24 (2005) 166-171
38. Song Y., Ridker P.M., Manson J.E., Cook N.R., Buring J.E., and Liu S. Magnesium intake, C-reactive protein, and the prevalence of metabolic syndrome in middle-aged and older US women. Diabetes Care 28 (2005) 1438-1444
39. Warnick G.R., Benderson J., and Albers J.J. Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol. 129 (1986) 101-123
40. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin. Chem. 28 (1982) 1379-1388
41. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18 (1972) 499-502
42. Bonora E., Targher G., Alberiche M., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23 (2000) 57-63
43. Dyer A.R., Cutter G.R., Liu K.Q., et al. Alcohol intake and blood pressure in young adults: the CARDIA Study. J. Clin. Epidemiol. 43 (1990) 1-13
44. Jacobs Jr. D.R., Hahn L.P., Haskell W.L., Pirie P., and Sidney S. Validity and reliability of short physical activity history: CARDIA and the Minnesota Heart Health program. J. Cardiopulm. Rehabil. 9 (1989) 448-459
45. McDonald A., Van Horn L., Slattery M., et al. The CARDIA dietary history: development, implementation, and evaluation. J. Am. Diet Assoc. 91 (1991) 1104-1112
46. Jewell N.P. Statistics for Epidemiology vol. 58 (2004), Chapman and Hall/CRC, Boca Raton
47. Steffensen F.H., Sorensen H.T., Brock A., Vilstrup H., and Lauritzen T. Alcohol consumption and serum liver-derived enzymes in a Danish population aged 30-50 years. Int. J. Epidemiol. 26 (1997) 92-99
48. Lee D.H., Ha M.H., and Christiani D.C. Body weight, alcohol consumption and liver enzyme activity - a 4-year follow-up study. Int. J. Epidemiol. 30 (2001) 766-770
49. Kirschner B.S., and Sutton M.M. Somatomedin-C levels in growth-impaired children and adolescents with chronic inflammatory bowel disease. Gastroenterology 91 (1986) 830-836
50. Thomas A.G., Holly J.M., Taylor F., and Miller V. Insulin-like growth factor-I, insulin like growth factor binding protein-1, and insulin in childhood Crohn's disease. Gut 34 (1993) 944-947
51. Beattie R.M., Camacho-Hubner C., Wacharasindhu S., Cotterill A.M., Walker-Smith J.A., and Savage M.O. Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease. Clin. Endocrinol. (Oxf) 49 (1998) 483-489
52. Katsanos K.H., Tsatsoulis A., Christodoulou D., Challa A., Katsaraki A., and Tsianos E.V. Reduced serum insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 levels in adults with inflammatory bowel disease. Growth Horm. IGF Res. 11 (2001) 364-367
53. Efstratiadis G., Tsiaousis G., Athyros V.G., et al. Total serum insulin-like growth factor-I and C-reactive protein in metabolic syndrome with or without diabetes. Angiology 57 (2006) 303-311
54. Renehan A.G., Atkin W.S., O'Dwyer S.T., and Shalet S.M. The effect of cigarette smoking use and cessation on serum insulin-like growth factors. Br. J. Cancer 91 (2004) 1525-1531
55. Madsen C., Nafstad P., Eikvar L., Schwarze P.E., Ronningen K.S., and Haaheim L.L. Association between tobacco smoke exposure and levels of C-reactive protein in the Oslo II Study. Eur. J. Epidemiol. 22 (2007) 311-317
56. Tracy R.P., Psaty B.M., Macy E., et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 2167-2176
57. Dietrich T., Garcia R.I., de Pablo P., Schulze P.C., and Hoffmann K. The effects of cigarette smoking on C-reactive protein concentrations in men and women and its modification by exogenous oral hormones in women. Eur. J. Cardiovasc. Prev. Rehabil. 14 (2007) 694-700
58. Hak A.E., Stehouwer C.D., Bots M.L., et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1986-1991
59. O'Callaghan P.A., Fitzgerald A., Fogarty J., et al. New and old cardiovascular risk factors: C-reactive protein, homocysteine, cysteine and von Willebrand factor increase risk, especially in smokers. Eur. J. Cardiovasc. Prev. Rehabil. 12 (2005) 542-547
60. McGreevy K., Hoel B., Lipsitz S., Bissada N., and Hoel D. Racial and anthropometric differences in plasma levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3. Urology 66 (2005) 587-592
61. Platz E.A., Pollak M.N., Rimm E.B., et al. Racial variation in insulin-like growth factor-I and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol. Biomar. Prev. 8 (1999) 1107-1110
62. Gapstur S.M., Kopp P., Chiu B.C., Gann P.H., Colangelo L.A., and Liu K. Longitudinal associations of age, anthropometric and lifestyle factors with serum total insulin-like growth factor-I and IGF binding protein-3 levels in black and white men: the CARDIA male hormone study. Cancer Epidemiol. Biomar. Prev. 13 (2004) 2208-2216
63. Henderson K.D., Goran M.I., Kolonel L.N., Henderson B.E., and Le Marchand L. Ethnic disparity in the relationship between obesity and plasma insulin-like growth factors: the multiethnic cohort. Cancer Epidemiol. Biomar. Prev. 15 (2006) 2298-2302
64. LaMonte M.J., Durstine J.L., Yanowitz F.G., et al. Cardiorespiratory fitness and C-reactive protein among a tri-ethnic sample of women. Circulation 106 (2002) 403-406